618 related articles for article (PubMed ID: 30806814)
21. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
22. Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.
Yu HA; Planchard D; Lovly CM
Am Soc Clin Oncol Educ Book; 2018 May; 38():726-739. PubMed ID: 30231382
[TBL] [Abstract][Full Text] [Related]
23. Breakthrough in targeted therapy for non-small cell lung cancer.
Ye Z; Huang Y; Ke J; Zhu X; Leng S; Luo H
Biomed Pharmacother; 2021 Jan; 133():111079. PubMed ID: 33378976
[TBL] [Abstract][Full Text] [Related]
24. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
25. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
26. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.
Michelotti A; de Scordilli M; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743191
[TBL] [Abstract][Full Text] [Related]
27. Emerging protein kinase inhibitors for non-small cell lung cancer.
Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
[TBL] [Abstract][Full Text] [Related]
28. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
Marmarelis ME; Langer CJ
Clin Lung Cancer; 2020 Sep; 21(5):395-406. PubMed ID: 32505631
[TBL] [Abstract][Full Text] [Related]
30. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological management of relapsed/refractory NSCLC with chemical drugs.
Karachaliou N; Sosa AE; Barron FB; Gonzalez Cao M; Santarpia M; Rosell R
Expert Opin Pharmacother; 2017 Feb; 18(3):295-304. PubMed ID: 28103738
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
33. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
34. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
35. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract][Full Text] [Related]
36. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
Cameron L; Solomon B
Curr Treat Options Oncol; 2015 Oct; 16(10):49. PubMed ID: 26318457
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
[TBL] [Abstract][Full Text] [Related]
38. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
39. New Targets in Non-Small Cell Lung Cancer.
Park SJ; More S; Murtuza A; Woodward BD; Husain H
Hematol Oncol Clin North Am; 2017 Feb; 31(1):113-129. PubMed ID: 27912827
[TBL] [Abstract][Full Text] [Related]
40. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Giuliani J; Martelli S; Remo A; Bonetti A
Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]